Kestrel Investment Management’s Myriad Genetics MYGN Stock Holding History

Kestrel Investment Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-229,925	Closed	-$6.58M	–	44
2019 Q3	$6.58M	Sell	229,925 -1,950	-0.8%	-$56.8K	3.27%	13
2019 Q2	$6.44M	Sell	231,875 -1,100	-0.5%	-$31.1K	3.05%	14
2019 Q1	$7.74M	Buy	+232,975	New	+$7.09M	3.57%	5
2015 Q2	–	Sell	-614,275	Closed	-$21.7M	–	49
2015 Q1	$21.7M	Sell	614,275 -26,100	-4%	-$934K	2.97%	8
2014 Q4	$21.8M	Sell	640,375 -13,450	-2%	-$477K	2.91%	10
2014 Q3	$25.2M	Sell	653,825 -22,900	-3%	-$854K	3.57%	5
2014 Q2	$26.3M	Sell	676,725 -12,000	-2%	-$446K	3.28%	5
2014 Q1	$23.5M	Sell	688,725 -10,825	-2%	-$335K	2.92%	10
2013 Q4	$14.7M	Sell	699,550 -154,925	-18%	-$3.92M	1.81%	24
2013 Q3	$20.1M	Buy	+854,475	New	+$24.3M	2.06%	20

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Kestrel Investment Management's MYGN Position: Q4 2019 in Review

Kestrel Investment Management sold out of Myriad Genetics (MYGN) in Q4 2019, closing a stake of 229,925 shares — an estimated $6.58M sold.

Kestrel Investment Management first reported a position in MYGN in Q3 2013 and held it in 10 quarters. The position peaked at $26.3M in Q2 2014. 227 funds tracked by Wall St. Rank hold MYGN as of Q4 2019.

Kestrel Investment Management reported no remaining Myriad Genetics position as of Q4 2019 after selling out during the quarter.
Kestrel Investment Management sold 229,925 Myriad Genetics shares in Q4 2019, an estimated $6.58M.
Kestrel Investment Management first reported a position in Myriad Genetics in Q3 2013 and held it in 10 quarters.
Kestrel Investment Management's Myriad Genetics position peaked at $26.3M in Q2 2014.
227 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2019.

Based on Kestrel Investment Management's 13F filing for Q4 2019, filed 13 Feb 2020.